NEWS

A number of important findings regarding MPNs were featured in June, at the European Hematology Association’s (EHA2022) Congress in Vienna. Some key highlights follow. How to select patients with myelofibrosis for transplantation and how to manage MF patients during a transplant procedure.   Related abstract: Should Transplantation Still Be Considered for Ph1-Negative Myeloproliferative Neoplasms in Transformation?   Jean Jacques… Read More »MPN News from 2022 EHA Congress

A number of important findings regarding MPNs were featured in June, at the 2022 American Society of Clinical Oncology (2022ASCO) Annual Meeting in Chicago. Some key highlights follow. Rusfertide Shown to Reduce Phlebotomy “The target in treating patients with PV (polycythemia vera) is to chronically maintain adequate hematocrit levels below 45 percent, which reduces the… Read More »MPN News from 2022 ASCO

Research Spotlight on Rebekka Schneider, MD, Director, Department of Cell and Tumor Biology, Aachen University, Germany, and Erasmus MC Cancer Institute, The Netherlands. In MPNs, your blood forming stem cell acquires a mutation, and this leads to more proliferation. In the beginning, you have too many blood cells. Then, in the course of the disease,… Read More »Identifying and Validating Actionable Biomarkers in MPN  

New York, N.Y., May 10, 2022 – MPN Research Foundation (MPNRF), a global organization driving research to find new and better treatments for myeloproliferative neoplasms (MPNs), a group of rare blood cancers, and Trialjectory, the AI-powered decision-support platform for patients, healthcare providers and pharmaceutical companies, today announced a joint collaboration to bring Trialjectory’s free, AI-powered clinical… Read More »MPN Research Foundation and Trialjectory Partner to Provide Advanced Clinical Trial Matching Services for Patients in Need

PhD Stanford University With so much variability of symptoms and progression among MPN patients, individualized treatment plans are critical in the management of essential thrombocythemia, polycythemia vera, and myelofibrosis. Personalized medicine in MPNs requires that we first address the challenge of patient genetic heterogeneity, according to Anandi Krishnan, PhD, including across the clinical spectrum of… Read More »Bridging a Patient’s Mutational Data and Clinical Observations to Help Predict Progression

Catriona Jamieson, MD, PhD, University of California, San Diego Why is it that only some people progress from polycythemia vera or essential thrombocythemia to myelofibrosis? And why do only some people with myelofibrosis progress to AML?   When Catriona Jamieson, MD, PhD, and her colleagues at University of California, San Diego, first asked these questions around… Read More »Studying MPNs in the Lab and in Space

https://www.youtube.com/watch?v=yaeHpBdRxJo The science of progression was the subject of a recent webinar hosted by MPN Advocacy & Education International, in partnership with the MPN Research Foundation. The recording is now available, featuring Raajit Rampal, MD, PhD, of Memorial Sloan Kettering Cancer Center, and MPNRF Chief Executive Officer Kapila Viges. Dr. Rampal serves as the foundation’s… Read More »ICYMI Webinar on Progression

Yelena Ginzburg, MD, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai Dr. Yelena Ginzburg’s research illustrates how basic research, clinical data, and clinical trial development inform each other in what is often a continuous loop between lab and clinic. Funded by a 2019-2021 MPN Challenge award, her work focuses on understanding why iron… Read More »From Lab to Clinic and Back

Our Scientific Advisory Board represents an extraordinary group of MPN thought leaders who contribute a broad range of medical, scientific, and short- and long-term strategic advice to the foundation. We greatly appreciate the commitment by all of the members of this outstanding volunteer board, and welcome five new members. • Radek Skoda, MD, PhD, University… Read More »MPN Leaders Added to Scientific Advisory Board

With a 21-year history of impactful MPN research, we’re proud of where we started, where we are, and most importantly, where we’re headed. Check out our IMPACT@21 story in this new digital report, featuring the voices of leading MPN researchers, clinicians, advocates and people living with ET, PV and MF.